AI-Discovered Drug Rentosertib Cleared for Inhalation Study in IPF
Insilico Medicine announced IND clearance for Rentosertib (ISM001-055) as an inhalation solution, marking a major clinical milestone for an AI-discovered candidate now moving to direct-to-lung testing in Idiopathic Pulmonary Fibrosis. The inhalation program follows positive Phase IIa data from the oral formulation and launches a Phase I study to assess safety and pharmacokinetics of inhaled delivery.
Targeting IPF with Precision Delivery
Rentosertib is an AI-identified TNIK inhibitor developed to treat IPF, a progressive and often fatal interstitial lung disease. Delivering the molecule via inhalation concentrates drug exposure in the lung, offering faster onset, higher local bioavailability, and lower systemic exposure compared with oral dosing. The upcoming Phase I study will evaluate tolerability, lung pharmacokinetics, and systemic levels to inform dose selection for future efficacy trials.
AI’s Proven Efficiency in Drug Development
This inhalation IND is the 13th program from Insilico’s pipeline to reach IND clearance, a pattern that underpins the company’s claim of platform reproducibility. Insilico reports that its Pharma.AI platform compresses typical discovery timelines from roughly 4.5 years to an average of 12 to 18 months from project start to preclinical candidate nomination, while requiring synthesis and testing of far fewer molecules. “This IND clearance validates Pharma.AI’s repeatable ability to bring AI-discovered molecules to clinic rapidly,” said Alex Zhavoronkov, CEO of Insilico Medicine.
A Landmark for AI in Clinical Trials
Beyond a single compound, Rentosertib’s inhalation IND acts as a proof point for generative AI applied across drug discovery and development. Consistent progression of multiple AI-originated candidates into human studies strengthens the argument that AI can reliably identify novel targets and fast-track therapeutic candidates across therapeutic areas, shortening the path from computational hypothesis to clinical testing.
For clinicians, investors, and researchers watching AI in biopharma, Rentosertib’s move to an inhalation Phase I is a visible validation of AI-driven efficiency and a signal that translational AI workflows are maturing into repeatable, clinic-ready outputs.
